Cabaletta BioInc., a biotechnology company focused on the discovery and development of cellular therapies for B cell-mediated autoimmune diseases, has appointed Anup Marda, MBA, as Chief Financial Officer effective immediately.

 

Marda joins Cabaletta with 17 years of financial leadership experience, most recently as Vice President and Head of Global Corporate Financial Planning & Analysis of Bristol-Myers Squibb (BMS).

 

“Anup’s breadth of financial experience across translational research, clinical operations, manufacturing, regulatory and commercial aspects of product development prepare him well for this role,” said Steven Nichtberger, co-Founder, CEO and Chairman of Cabaletta Bio. “Anup’s experience at BMS will be particularly relevant as we anticipate rapidly evolving to become a clinical stage company while expanding our pipeline and our emerging in-house translational research and advanced manufacturing capabilities.”

 

Marda was an accomplished leader in the BMS finance organization who partnered closely with R&D, clinical and commercial colleagues. During his 17-year career at BMS, he held many roles with increasing responsibility. Most recently, he was Vice President, Head of Global Corporate Financial Planning & Analysis.

 

Previously, Marda spent four years in leadership roles supporting R&D, including leading a team responsible for providing financial and business support for multiple groups, including: Discovery, Translational Medicine, Pharmaceutical Development, Global Clinical Operations, Global Regulatory, Operations and Global Medical. He was alsohead of Finance, R&D Portfolio Management, World-wide Commercial and Global Medical, a role created at the time to better integrate R&D, commercial and medical decision-making. Mr. Marda was also the Assistant Treasurer, Head of Capital Markets as well as Executive Director, Finance of the U.S. Immunoscience business. Marda earned his MBA from Krannert School of Business, Purdue University and a Bachelor of Technology in Chemical Engineering from the Indian Institute of Technology (IIT) Bombay.

 

“My initial attraction to Cabaletta was its novel CAAR T cell therapy platform designed to treat very challenging B cell-mediated autoimmune diseases that have, up to now, been less than adequately managed,” said Marda. “In addition, the top-tier management team, highly regarded scientific advisors and license and research collaboration with the University of Pennsylvania convinced me that joining the Cabaletta team would be an exciting new challenge. I look forward to working with my new colleagues in bringing this new platform and products to patients.”

Marda joins Cabaletta with 17 years of financial leadership experience, most recently as Vice President and Head of Global Corporate Financial Planning & Analysis of Bristol-Myers Squibb (BMS).